← All trials
NCT04435379
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2020
- Primary completion
- May 31, 2021
- Completion date
- May 31, 2021
- First posted
- Jun 17, 2020
- Last posted
- Jun 17, 2020
- Enrollment
- 2038
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Vakzine Projekt Management GmbHLead sponsor
- FGK Clinical Research GmbHCollaborator
- Vakzine Projekt Management GmbHStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.